BIOHAVEN PHARMACTL HLDG CO L's ticker is BHVN and the CUSIP is G11196105. A total of 224 filers reported holding BIOHAVEN PHARMACTL HLDG CO L in Q2 2021. The put-call ratio across all filers is 1.19 and the average weighting 0.8%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2022 | $62,131,000 | -3.7% | 524,000 | +12.0% | 1.20% | +13.8% |
| Q4 2021 | $64,495,000 | +23.5% | 468,000 | +24.5% | 1.06% | +19.2% |
| Q3 2021 | $52,230,000 | +7.6% | 376,000 | -24.8% | 0.88% | +1.8% |
| Q2 2021 | $48,540,000 | -29.0% | 500,000 | -50.0% | 0.87% | -44.6% |
| Q1 2021 | $68,350,000 | +39.4% | 1,000,000 | +74.8% | 1.57% | -5.9% |
| Q4 2020 | $49,026,000 | -16.2% | 572,000 | -36.4% | 1.67% | -21.4% |
| Q3 2020 | $58,509,000 | +60.1% | 900,000 | +80.0% | 2.12% | +32.4% |
| Q2 2020 | $36,555,000 | +1.7% | 500,000 | -52.7% | 1.60% | -27.9% |
| Q1 2020 | $35,936,000 | +7.9% | 1,056,000 | +72.5% | 2.22% | +15.6% |
| Q4 2019 | $33,317,000 | +38.2% | 612,000 | +5.9% | 1.92% | +20.3% |
| Q3 2019 | $24,114,000 | +244.2% | 578,000 | +261.2% | 1.60% | +261.5% |
| Q2 2019 | $7,006,000 | – | 160,000 | – | 0.44% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| RP Management, LLC | 2,111,111 | $144,294,000 | 54.16% |
| Knoll Capital Management, LLC | 856,844 | $58,565,000 | 38.16% |
| ORACLE INVESTMENT MANAGEMENT INC | 2,123,271 | $145,126,000 | 21.73% |
| KINGDON CAPITAL MANAGEMENT, L.L.C. | 860,261 | $58,799,000 | 6.01% |
| ARS Investment Partners, LLC | 561,442 | $38,375,000 | 4.46% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 176,400 | $12,057,000 | 3.19% |
| Eventide Asset Management | 2,015,000 | $137,725,000 | 2.04% |
| Avidity Partners Management LP | 1,049,800 | $71,754,000 | 1.98% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 50,089 | $3,424,000 | 1.87% |
| Nicholas Investment Partners, LP | 375,654 | $25,676,000 | 1.79% |